GMAT Club World Cup 2022 (DAY 8): The year-end sales report from a vet

ANSWER D

Conclusion: the managers of the vaccine company did not reduce the projected revenues from Minkvac for the next year, a value that was estimated last year.

Premise: there was no change in the revenues from the sales of the vaccine Minkvac, in spite of regulation significantly curbing the use of mink furs in which Minkvac is used

Gap: Maybe the revenue remained the same because most of the sales were done in the 1st half of the year before the regulation was passed

A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year. This is the opposite of what we want. This supports the argument

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned. Marketing or sales of Racoonvac has nothing to do with Minkvac's revenue

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be. Effectiveness is irrelevant here

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter. CORRECT, since most of the sales were done in 1st quarter, hence the regulation didn't affect the revenue.

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected. This does not explain why the projection will not be met this year

A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year. - Does not weaken

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned. - Irrelevant

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be. - Irrelevant

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter. - This weakens the argument

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected. - Does not weaken

Regulation to ban using mink fir for garment manufacture was passed middle of this year but still revenues of this year were the same as last year. Based on this, people manufacturing Minkvac have not changed their projection for the next year, a value that was estimated last year.
We need to determine what would most weaken the stance and result in their revenue projections not being met the next year.
Let us examine the answer options:

A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year.
Irrelevant, we are only concerned with Minkvac. ELIMINATE

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned.
Irrelevant again, concerned with Minkvac

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be.
Close but not enough. ELIMINATE

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter.
Yes! Minkvac is necessary for minks used for garment manufacture. Bill was passed middle of the year and all the vaccinees for this year were already sold at the beginning of this year before the bill came but next year it will not sell before of the ban. ANSWER

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected.
If them leaving did not affect this year, it will not affect next also. ELIMINATE

Answer - D

ANSWER D for me

Which of the following options, if true, indicates most strongly that the projection made by the managers for the next year mentioned in the passage would most likely not be met? => We should find a fact or a reason explaining why sales of minkvac did not change this year and will change next year.


Logically, the sales of the vaccinne Minkvac should drop as the regulation curbing the use of mink to manufacture garments will then drop the use of Minkvak which is mandatory when to be used to manufacture garments.



(guessing) So we have 2 possibilities :

- Either, the sales this year where part of a contract signed in last year or earlier the same year so that there were no choice to buy it as already planned ;

- Or the price of Minkvak rose this year to compensate the drop in sales so that revenue is the same => in that case it is likely that next year, companies buying minkvac may try to find another suitable way (cheaper for eg) to manufacture garments.


So we can try to find an argument that sustain One of these possibilities.

A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year. has nothing to do with sales of Minkvac, Minkvac is mandatory for mink => INCORRECT

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned. => has nothing to do with sales of Minkvac as minkvac is mandatory here, or at least it will increase the sales of minkvac so that the projection made by managers may be met => INCORRECT

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be. We have no proof that effectiveness of vaccine is needed, Minkvac is mandatory to be administered, not to be effective => INCORRECT

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter. => This is the best solution that goes in the same way as our first guess => CORRECT

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected. => We have no proof or no reason to think that will affect sales of Minkvac => INCORRECT

The year-end sales report from a veterinary vaccine company states the following:

A regulation significantly curbing the use of mink furs to manufacture garments was passed during the middle of this year. However, compared to last year, there was no change in the revenues from the sales of the vaccine Minkvac that is mandatory to be administered to all the minks that are used to manufacture garments.

Because of the above report, the managers of the vaccine company did not reduce the projected revenues from Minkvac for the next year, a value that was estimated last year.

Which of the following options, if true, indicates most strongly that the projection made by the managers for the next year mentioned in the passage would most likely not be met?


A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year. Incorrect

irrelevant

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned. Incorrect

irrlevant

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be. Correct

only possible answer choice

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter. Incorrect

so sales will not decrease because all vaccine will be sold in first quarter

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected. Incorrect

we can say, next years sales will not be affected

Imo D

A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year.
Out of scope. We need to see the revenues from the sales of the vaccine Minkvac.
B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned.
Same as A.
C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be.
Although the effectiveness has decreased, the revenue this year has not changed.
D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter.
Correct. Ideally this year the revenue should decrease. The reason that the revenue didn't change this year is because of the disease. This may not happen next year.
E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected.
It means the revenue will not be affected next year too.

The year-end sales report from a veterinary vaccine company states the following:

A regulation significantly curbing the use of mink furs to manufacture garments was passed during the middle of this year. However, compared to last year, there was no change in the revenues from the sales of the vaccine Minkvac that is mandatory to be administered to all the minks that are used to manufacture garments.

Because of the above report, the managers of the vaccine company did not reduce the projected revenues from Minkvac for the next year, a value that was estimated last year.

Which of the following options, if true, indicates most strongly that the projection made by the managers for the next year mentioned in the passage would most likely not be met?


A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year.
Does not weaken the argumnet

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned.
Does not weaken the argumnet

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be.
Does not weaken the argumnet

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter.
Correct

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected.
Does not weaken the argumnet

The year-end sales report from a veterinary vaccine company states the following:

A regulation significantly curbing the use of mink furs to manufacture garments was passed during the middle of this year. However, compared to last year, there was no change in the revenues from the sales of the vaccine Minkvac that is mandatory to be administered to all the minks that are used to manufacture garments.

Because of the above report, the managers of the vaccine company did not reduce the projected revenues from Minkvac for the next year, a value that was estimated last year.

Which of the following options, if true, indicates most strongly that the projection made by the managers for the next year mentioned in the passage would most likely not be met?


A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year.

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned.

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be.

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter.

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected.

The answer is D.

Official Explanation is pinned as BEST Reply HERE.

Premise - No change in revenue from Minkvac from last year even after curb on mink garment
Conclusion - Revenue will be same next year

We need to find a reason that conclusion will be weakened

POE
A. A new vaccine, Catvac, developed by the company would bring in significant revenues next year. - Catvac is OUT OF SCOPE - INCORRECT

B. Development of the company’s another vaccine called Racoonvac was hindered because of safety concerns and will not be marketed next year as previously planned. - Racoonvac is OUT OF SCOPE - INCORRECT

C. The latest clinical trial results for Minkvac have proven that the effectiveness of the vaccine is only 80% as compared to 90% previously thought to be. New reason has come to light. This can hinder the projections. -- CORRECT

D. Minkvac is a vaccine against a seasonal disease that spreads in the second quarter of the year and hence almost all the vaccines are sold in the first quarter. - The results are based on year on year performance not on a quarterly basis. -- INCORRECT

E. Even though some high-performing sales managers responsible for Minkvac sales left the company last year, the revenues from Minkvac this year are not affected. --- Gives support to conclusion -- OPPOSITE - INCORRECT

Hello from the GMAT Club VerbalBot!

Thanks to another GMAT Club member, I have just discovered this valuable topic, yet it had no discussion for over a year. I am now bumping it up - doing my job. I think you may find it valuable (esp those replies with Kudos).

Want to see all other topics I dig out? Follow me (click follow button on profile). You will receive a summary of all topics I bump in your profile area as well as via email.